Abstract OBJECTIVE: To study the effect of budesonide (BUD) on RORγt expression in the pulmonary tissue of asthmatic mice and mechanisms of BUD in the treatment of asthma. METHODS: Blab/c asthmatic mouse model was induced by ovalbumin (OVA). Thirty female mice were randomly divided into three groups: control, asthmatic and BUD-treated. IL-17 levels in bronchoalveolar lavage fluid (BALF) and serum were measured using ELISA. Total and differential cell counts in BALF were measured. Airway inflammation was evaluated by hematoxylin and eosin staining. IL-17 mRNA and RORγt mRNA expression were measured by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: RORγt mRNA and IL-l7 levels in the asthmatic group were significantly higher than in the control group (P<0.01). BUD treatment significantly decreased RORγt mRNA and IL-l7 levels compared with the asthmatic group (P<0.01). Compared with the control group, total, neutrophil and eosinophil cell count in BALF increased significantly in the asthmatic group (P<0.01). After BUD treatment, counts of total, neutrophil and eosinophil cells in BALF were significantly reduced (P<0.01) and were similar to in the control group. Inflammatory reactions in the respiratory tract were significantly alleviated in the BUD treated group. CONCLUSIONS: RORγt and IL-l7 levels in the pulmonary tissue of asthmatic mice increase and this may be associated with the pathogenesis of asthma. BUD can inhibit RORγt and IL-17 and thus reduces lung inflammation.
BIAN Fang-Fang,WANG Jun,LU Ming et al. RORγt expression in the pulmonary tissue of asthmatic mice and the inhibitory effects of budesonide[J]. 中国当代儿科杂志, 2012, 14(08): 628-631.
BIAN Fang-Fang,WANG Jun,LU Ming et al. RORγt expression in the pulmonary tissue of asthmatic mice and the inhibitory effects of budesonide[J]. CJCP, 2012, 14(08): 628-631.
［2］Kumar RK, Herbert C, Kasper M. Reversibility of airway inflammation and remodelling following cessation of antigenic challenge in a model of chronic asthma［J］. Clin Exp Allergy, 2004, 34(11): 1796-1802.
［3］Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages［J］. Nat Immunol, 2005, 6(11): 1123-1132.
［4］Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effect or TH17 and regulatory T cells［J］. Nature, 2006, 441 (7090): 235-238.
［5］Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family［J］. J Leukoc Biol, 2002, 71(1): 1-8.
［6］Jetten AM. Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs)［J］. Curr Drug Targets Inflamm Allergy, 2004, 3(4): 395-412.
［8］Sakai K, Yokoyama A, Kohno N, Hiwada K. Effect of different sensitizing doses of antigen in a murine model of atopic asthma［J］. Clin Exp Immunol, 1999, 118 (1): 915.
［9］Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17［J］. Nat Immunol, 2005, 6(11): 1133-1141.
［11］Sun YC, Zhou QT, Yao WZ. Sputum interleukin-17 is increased and associated with airway neutrophilia in patients with severe asthma ［J］. Chin Med J (Engl), 2005, 118 (11): 953-956.
［12］Ivanov II, McKenzie BS, Zhou L, Tadokoro CE,Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL17+ T helper cells［J］. Cell, 2006, 126 (6): 1121-1133.
